Developing unique RNA Therapies for Cardiovascular Disease

Targeting Pulmonary Hypertension and Coronary Artery Disease

Our Vision

Effective and safe RNAi – mRNA Therapy
Selective gene silencing and overexpression in vascular endothelium

VasoRX is leading the translation of innovative RNA therapy technologies for the LNP delivery of RNAi or mRNA in the treatment of cardiovascular disease. VasoRX's team envisions a future where fibrosis, vascular remodeling and chronic vascular inflammation underlying diseases, like atherosclerotic coronary artery disease and pulmonary hypertension, no longer impose incurable and life threatening tissue damage or progression into heart or respiratory failure.

VasoRx Technology

Unique cationic lipoprotein nanoparticles are capable of delivering non-coding polynucleotides specifically to the vascular endothelium to modify chronic vascular inflammation, fibrosis and vascular remodeling: A True Game-Changer in Cardiovascular Disease

Our unique platform of polymeric lipoprotein nanoparticles (LNP) is able to specifically deliver non-coding RNA, such as, e.g., siRNA, to the endothelial inner layer of the vasculature with high efficiency, and mediate a durable silencing of selected genes for over a period of weeks to months, without any detectable inflammatory infiltration. For example, administration of our LNP encapsulating siRNA to animal models in pre-clinical studies demonstrated silencing of TGF-beta pathway in endothelium, and for the first time, reversal of vascular changes seen in pulmonary hypertension (PH) , transplant vasculopathy, and atherosclerosis. These vascular changes drive the progression of these diseases, and ultimately lead to respiratory failure (PAH), organ failure (transplant), or progressive ischemic heart failure (CAD).

Learn more about our technology

Company Development

6 years of R&D to establish a cutting edge therapeutic for modern RNAi medicine.

2014

Ground breaking discovery and publication in Nature by the pioneers of RNAi/LNP technology, profs Robert Langer and Dan Anderson from MIT of an unique LNP platform that is able to specifically transduce vasculature (i.e. vascular endothelium; Nature Nanotechnology 2014).
Exploration of biological process and molecular regulation of chronic vascular inflammation and remodeling at Yale University (Data published in Nature)
Data of therapeutic effect of LNP-TGFbR1 in Atherosclerosis published in Nature (Pei Yu et al, Nature Metabolism)

2018

Founding of VasoRx

2019

Exclusive license of MIT patent rights related to LNP delivery of siRNA and miRNA for the treatment and/or prevention of human cardiovascular diseases

2021

Development of unique VasoRx LNP platform, that is able to transduce 93% of all endothelial cells after a single iv bolus without any inflammatory changes

2022